In French Guiana, malaria is endemic and two species predominate: P. falciparum and P. vivax. The treatment for Plasmodium vivax malaria is nivaquine for 3 days against circulating blood parasites associated with primaquine for 14 days against hypnozoites. Primaquine can cause iatrogenic haemolytic anemia in patients with favism, i.e. G6PD deficiency. This anemia can be severe enough to lead to the death of the deficient patient. Thus, the WHO and HCSP recommendations indicate that a quantitative assay of the activity of this enzyme must be carried out before its prescription. This deficiency is a recessive hereditary disease linked to the X chromosome characterized by more or less low levels of enzymatic activity which depends on the genotype of the patients but not only, because the level of activation of the X chromosome for each cell is varied. At present, obtaining a G6PD assay in French Guiana is long since it is done in mainland France and the pre-analytical conditions are quite demanding. Thus, in areas of transmission of P. vivax, patients generally have a bout of revival before being prescribed primaquine. This period includes: the G6PD assay remote from the access, obtaining the result then the administrative authorization to deliver primaquine. The objective of this study is to evaluate the performance of a rapid quantitative test for the determination of G6PD activity per gram of hemoglobin, “STANDARD G6PD” from SD BIOSENSOR for the detection of deficient patients in comparison with the reference enzymatic method. For this study, 150 participants will be included based on their G6PD activity (50 subjects with severe deficiency, 50 subjects with intermediate G6PD activity and 50 subjects with normal activity). These inclusions and dosage will be done in the different municipalities of French Guiana, right in the field, in degraded conditions, to test the performances and the robustness of the method compared to the gold standard enzymatic method.